Discussions in the EU have evolved from scientific principles of #biosimilarity to market access initiatives. Now, one @medicinesforEU expert argues they're in the age of investigating sustainability. Read her thoughts on what this means on @OnBiosimilars https://t.co/F2GlGObLeF